Exelixis Inc. (EX9)

Overview

Exelixis, Inc. is an oncology-focused biopharmaceutical company dedicated to the development and commercialization of new medicines for the treatment of difficult-to-treat cancers. With its headquarters in Alameda, California, the company has been advancing cancer care since its inception in 1994, initially operating under the name Exelixis Pharmaceuticals, Inc. before rebranding to Exelixis, Inc. in February 2000. Exelixis has a robust portfolio of products available in the United States, alongside a dynamic pipeline of investigational drugs in development, reflecting its commitment to improving outcomes for patients facing complex cancer challenges. The company has established a substantial network of research collaborations and license agreements with leading pharmaceutical and biotechnology companies, including Ipsen Pharma SAS, Takeda Pharmaceutical Company Ltd., F. Hoffmann-La Roche Ltd., and Bristol-Myers Squibb Company, among others. This extensive collaboration network supports the company's strategic approach to drug development and enhances its ability to bring innovative cancer treatments to market.

Products and Services

• CABOMETYX: This tablet formulation is designed for the treatment of patients with advanced renal cell carcinoma who have previously received anti-angiogenic therapy. CABOMETYX operates as an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors, highlighting its multifaceted approach to targeting cancer growth.
• COMETRIQ: Available as capsules, COMETRIQ targets progressive and metastatic medullary thyroid cancer. Like CABOMETYX, COMETRIQ is derived from cabozantinib and inhibits several tyrosine kinases critical to cancer proliferation.
• COTELLIC: This product is an inhibitor of MEK and is used in a combination regimen to treat certain forms of advanced melanoma. It showcases Exelixis's commitment to developing combination therapies that target various pathways involved in cancer growth.
• MINNEBRO: An oral non-steroidal selective blocker of the mineralocorticoid receptor, MINNEBRO is approved for the treatment of hypertension in Japan. It represents Exelixis's efforts in addressing conditions that may accompany or result from cancer treatment.
• Zanzalintinib: Currently in development, zanzalintinib is a potent, next-generation oral tyrosine kinase inhibitor (TKI) that targets VEGF receptors and the TAM kinases (TYRO3, AXL, and MER). This investigational drug reflects Exelixis's ongoing research into novel cancer treatments.
• XB002: Also under development, XB002 is a next-generation tissue factor (TF)-targeting antibody-drug conjugate (ADC) administered via intravenous infusion. It consists of a human monoclonal antibody against TF conjugated to an auristatin-based microtubulin inhibitor payload, marking a cutting-edge approach to cancer therapy.